Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001839516-22-000004
Filing Date
2022-12-01
Accepted
2022-12-01 20:09:28
Documents
1
Period of Report
2022-11-29

Document Format Files

Seq Description Document Type Size
1 FORM 4 wf-form4_166994335109527.html 4  
1 FORM 4 wf-form4_166994335109527.xml 4 9226
  Complete submission text file 0001839516-22-000004.txt   10586
Mailing Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618
Business Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618 (949) 409-9820
Tarsus Pharmaceuticals, Inc. (Issuer) CIK: 0001819790 (see all company filings)

EIN.: 814717861 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 15440 LAGUNA CANYON ROAD, SUITE 160 IRVINE CA 92618
Business Address
Whitfield Dianne C. (Reporting) CIK: 0001839516 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39614 | Film No.: 221440058